Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Amortizatization of Intangibles: 2022-2025

Historic Amortizatization of Intangibles for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $800,000.

  • Day One Biopharmaceuticals' Amortizatization of Intangibles rose 33.33% to $800,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 130.18%. This contributed to the annual value of $6.4 million for FY2024, which is 36.60% down from last year.
  • Day One Biopharmaceuticals' Amortizatization of Intangibles amounted to $800,000 in Q3 2025, which was down 0.00% from $800,000 recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Amortizatization of Intangibles ranged from a high of $5.3 million in Q2 2023 and a low of $47,000 during Q1 2022.
  • Its 3-year average for Amortizatization of Intangibles is $1.9 million, with a median of $1.3 million in 2024.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first spiked by 4,040.94% in 2023, then plummeted by 94.30% in 2024.
  • Over the past 4 years, Day One Biopharmaceuticals' Amortizatization of Intangibles (Quarterly) stood at $1.7 million in 2022, then fell by 8.74% to $1.6 million in 2023, then surged by 79.12% to $2.8 million in 2024, then skyrocketed by 33.33% to $800,000 in 2025.
  • Its Amortizatization of Intangibles stands at $800,000 for Q3 2025, versus $800,000 for Q2 2025 and $4.2 million for Q1 2025.